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We have determined the structure of a complex of influenza hemagglutinin (HA) with an antibody that binds simultaneously
to the membrane-distal domains of two HA monomers, effectively cross-linking them. The antibody prevents the low pH
structural transition of HA that is required for its membrane fusion activity, providing evidence that a rearrangement of HAINTRODUCTION
Hemagglutinin (HA), the major influenza virus surface
glycoprotein, has two functions in infection: (i) it binds
the virus to its cellular receptors, sialic acid residues of
glycoproteins or glycolipids, and (ii) following endocyto-
sis it mediates the low-pH-induced fusion of viral and
cellular membranes to permit entry of the genome–tran-
scriptase complex into the cell (for a review, see Skehel
and Wiley, 2000). Structurally, HA is a trimer of identical
subunits, each of which consists of a membrane-proxi-
mal helix-rich stem structure and a membrane-distal
receptor-binding globular domain. HA interacts with in-
fectivity-neutralizing antibodies and as a consequence of
immune pressure, it is the virus component which is
important in antigenic drift that results in recurrent epi-
demics of influenza. In studies of the antigenicity of HA,
monoclonal antibodies directed against this molecule
have been prepared (see Wiley and Skehel, 1987, for a
review) and here the structure of a complex of the HA of
X31 virus (a strain adapted to laboratory growth condi-
tions, the hemagglutinin of which is identical to that of
the A/Hong Kong/1/68 (H3N2) virus) with one of these
antibodies provides insight into the low pH structural
transition required for fusion.
The low pH transition involves irreversible conforma-
tional changes in HA that have been defined by struc-
tural data from two different sources. First, electron mi-
croscopy, chemical cross-linking (Ruigrok et al., 1986),
and size estimates of HA fragments in solution (Bizebard
et al., 1995) indicate that dissociation of the HA mem-
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70brane-distal domains occurs at low pH. Second, X-ray
crystal structures of proteolytic fragments of low-pH-
treated HA define conformational changes in the helical
stem of HA (Bullough et al., 1994) that apparently deliver
its fusion peptide to the target membrane (Skehel et al.,
1982; Tsurudome et al., 1992) and indicate that the mem-
brane-distal domains, when cocrystallized with an Fab,
are monomeric (Bizebard et al., 1995). These structural
changes were prevented in site-specific mutants con-
taining novel inter-subunit disulfide bonds that cross-
linked the membrane-distal domains (Godley et al.,
1992). The epitope of the antibody that we have studied
here comprises residues of two HA monomers which are
effectively cross-linked in the trimer by interaction with
Fabs; in the complex the HA structure is mostly un-
changed compared to that of uncomplexed HA. As a
consequence, antibody binding prevents the low-pH-in-
duced structural transition in HA. Our results demon-
strate that membrane fusion requires a structural reor-
ganization of HA membrane-distal domains, which leads
to their detrimerization.
RESULTS AND DISCUSSION
Structure of the antibody–HA complex
The structure of the complex of the Fab with HA was
determined at 3.5 Å resolution (Table 1). The Fab binds
the HA membrane-distal surface (Fig. 1a). The whole HA
and the Fabs are in readily interpretable electron density,
and the conformation of the residues in the antibody–HA
interface is clearly defined (Fig. 1b). The general features
of the interface are within the range found for other
antibody–antigen complexes (Davies and Chacko, 1993).
There is no overall change of HA structure upon complex
formation: the root mean square deviation—rmsd—ofmembrane-distal domains is an essential component of th
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that expected from the 0.5 Å average atomic position
error estimated from a Luzzati plot (Luzzati, 1952). The
only significant change upon antibody binding is the
position of HA residue Arg189 (rmsd of atomic positions,
3 Å) which in its conformation in the uncomplexed HA
crystal structure would have prevented the interaction
we observe here. Five HA surface residues are com-
pletely buried in the HA–Fab interface (their solvent-
accessible surface in the complex is smaller than 5 Å2):
residues 136, 186, 190, 193, and 226. The affinities of the
Fab for two mutant viruses (see Materials and Methods)
that differ from X31 at two of these positions (residues
193 and 226) (Daniels et al., 1987) were found to be
reduced by more than 500-fold in an ELISA assay, con-
firming that the Fab binds to HA as observed in the
structure. On the HA side of the interface, residues
largely buried upon complex formation comprise amino
acids from two HA monomers (Fig. 1c). Most of the
interface (about 1410 Å2 of a total of 1860 Å2) is contrib-
uted by one monomer in which amino acids at positions
of the right side (residues 136 and 137), the rear (residue
190), the bottom (residue 153), and the left side (residues
225 and 226) of the sialic acid receptor-binding site (Weis
et al., 1988) are buried in the complex so that binding of
sialyated receptors in this site would be prevented by
bound antibody. Other residues of this monomer that are
buried in the interface are in a protruding loop (residues
156, 158, and 159) close to the receptor-binding site,
which has been suggested to be important as an anti-
body-binding site (Wiley et al., 1981); at the N-terminal
end of the short -helix (residues 186, 187, and 189) that
constitutes the back wall of the receptor-binding site;
and on the membrane-distal side of the receptor-binding
site (residues 192 and 193). Residues from the other
monomer are contributed by the second strand of the
-structure that constitutes most of the receptor-binding
domain (residues 162, 163, and 165) and by the loop
joining the first strand to the second strand of this struc-
ture (residues 126 and 128).
In the HA:Fab complex two Fabs are bound to one HA
trimer, which is also the stoichiometry of the purified
HA:Fab complex in solution (Gigant et al., 2000). This
stoichiometry differs from the 3:1 or 1:1 stoichiometries
of other antibody:HA complexes characterized so far. In
the case of the 3:1 antibody–HA complexes, with one
binding site on each HA monomer, direct evidence has
been provided by two crystal structures (Fleury et al.,
1999, 2000) and electron microscopy (Wrigley et al.,
1983); evidence for a 1:1 antibody–HA complex has been
provided by analytical centrifugation (Gigant et al., 2000)
and electron microscopy (Wrigley et al., 1983) in the case
of an antibody that selects a mutant HA changed at a
residue near the trimer interface on the tip of the mole-
cule, a site sufficiently large for only one antibody mol-
ecule to bind. In the 2:1 complex we study here, the
HA-binding sites of both Fabs are identical and, because
of the threefold symmetry of the HA trimer, a third poten-
tial Fab binding site is free. An Fab with the conformation
of either of the two bound Fabs can be docked at the free
site identically to the two bound Fabs, without any steric
hindrance by them (data not shown). Nevertheless, the
unprecedented stoichiometry, observed both in the
structure and in solution, implies that the affinity of this
third Fab for the 2:1 complex is significantly lower than
those of the two bound Fabs. This appears to be due to
the fact that in the complex there is an interaction be-
tween the two Fab heavy chain constant domains that
involves residues of the three stranded -pleated sheet
of these domains (Fig. 1a) burying about 250 Å2. Despite
that relatively small buried surface (Janin and Rodier,
1995) the 2:1 complex is stabilized relative to the 3:1 or
1:1 stoichiometry alternatives.
The antibody prevents HA low pH structural transition
The epitope of each Fab of the complex comprises
residues from two HA subunits of the trimer (see above)
so that the three HA monomers of the trimer are effec-
tively cross-linked by the two Fabs of the complex. This
provides an opportunity to study the influence of the
cross-linking of HA membrane-distal domains on the low
pH HA structural transition. Cross-linking of the mem-
brane-distal globular domains by disulfide bonds was
TABLE 1
Crystallographic Data and Refinement Statistics
Data collection statistics
Space group P21 21 2
Unit cell (Å) a  143.0 Å, b  315.6 Å,
c  97.0 Å;       90°
Resolution 25–3.5 Å
Number of reflections 54,923
Completeness (%)a 98.2 (98.2)
Redundancya 3.9 (2.9)
R sym (%)
a,b 12.8 (42.3)
I/(I)a 5.3 (1.8)
Refinement statistics
Resolution 25–3.5 Å
R (%) c 25.6
R free (%) 32.4
Number of atoms 18,473
Mean B factor (all atoms) (Å2) 47.9
Rms deviations from ideality
Bond lengths (Å) 0.016
Bond angles (°) 2.0
Sigmaa coordinate error (Å) 0.61
a The number in parentheses is the value in the 3.69- 3.5-Å resolution
shell.
b R sym   jI j  I/I, where I j is the jth intensity measure-
ment for a reflection and I is the mean intensity for multiply recorded
reflections.
c R  F obs  F calc/F obs for F  2.5 . R free is calculated with
5% of the reflections, which are not included in the refinement; 48,988
reflections were included in the refinement.
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shown to prevent the fusion-pH-induced changes in
structure and membrane fusion (Godley et al., 1992),
although the extent of possible structural changes result-
ing from the novel disulfide bonds was not directly es-
tablished. The structure of the HA:Fab complex studied
here demonstrates that there is no significant overall
change between the structures of uncomplexed and Fab-
cross-linked HA.
Detrimerization of the HA membrane-distal globular
domains was detected by the onset of HA trypsin sen-
sitivity; trypsin cleavage sites are at positions 27 and 224
of HA, which are not accessible in the neutral pH struc-
ture (Skehel et al., 1982). HA or its complex with a control
antibody, the epitope of which is contained in an HA
monomer (Daniels et al., 1983; Fleury et al., 1999), is
completely digested after short exposure to pH 4.6; by
comparison, the HA:Fab complex discussed here
showed much lower trypsin sensitivity, even at pH 4.2
(Fig. 2a). The antibody does not prevent trypsin digestion
of HA that has undergone the low pH transition (data not
shown). In parallel experiments we also monitored ag-
gregation of HA that results from exposure of the fusion
peptide at low pH. The results in Fig. 2b indicate that the
HA:Fab complex, with a sedimentation coefficient similar
to that of neutral pH HA, remains soluble after exposure
to pH 4.2. By contrast HA incubated at low pH without
antibody is aggregated. The small amount of HA that is
digested or aggregates in the presence of the antibody is
probably due to the small proportion of uncomplexed HA
that coexists with the HA:Fab complex and undergoes
the low pH transition, which is irreversible (Skehel et al.,
1982). We therefore conclude from our results that cross-
linking of HA membrane-distal domains in their neutral
pH structure prevents their detrimerization at low pH and
prevents the extrusion of the fusion peptide.
Inhibition of HA-mediated membrane fusion is an at-
tractive target for anti-influenza drugs (Bodian et al.,
1993; Staschke et al., 1998). Antibodies, such as the one
we studied, that bind in or near the receptor binding site
to prevent the conformational change required for mem-
brane fusion also block receptor binding. Distinction
between the relative importance of these consequences
of antibody binding for infectivity neutralization has not
been made but since receptor binding precedes mem-
brane fusion its inhibition is presumed to be more rele-
vant. However, prevention of HA-mediated membrane
fusion by cross-linking HA without affecting receptor
binding would also represent a mechanism on which to
FIG. 1. The structure of the HA:Fab complex. (a) Ribbon diagram of the complex showing the two Fabs (green) bound to an HA trimer (each monomer
is synthesized as a single polypeptide chain that is posttranslationally processed to yield two polypeptide chains; HA1, at the N-terminal end, is in
blue and HA2, at the C-terminal end, is in red). The receptor-binding sites where contacts are established with these Fabs are highlighted in yellow.
(b) Stereo close-up of an omit 2Fo-Fc electron density map (Brunger et al., 1998) in the HA–Fab interface, contoured at the 1- level. Fab residues
are in green and HA residues in blue. This figure was drawn with Bobscript (Esnouf, 1997). (c) Stereo close-up of the epitope; the HA polypeptide
chain is modeled as a blue ribbon on which side chains are grafted. Residues represented are those that belong to the receptor-binding site (yellow),
those that belong to the receptor-binding site and are also in the epitope (orange), and other residues of the epitope (green). The monomer of HA
that contributes most of the residues of the epitope is in darker colors. Figures (a) and (c) have been drawn with Molscript (Kraulis, 1991) and raster3D
(Merritt and Bacon, 1997).
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base the development of molecules of use as anti-influ-
enza drugs.
MATERIALS AND METHODS
Virus and proteins: purification and crystallization
We purified X31 virus and the bromelain-released
ectodomain of X31 hemagglutinin (BHA) as described
previously (Brand and Skehel, 1972). The antibody and
Fab were produced and purified according to Gigant et
al. (2000). Crystallization and characterization of the Fab
complex with X31 BHA have also been described (Gigant
et al., 2000).
Structure determination and refinement
The structure of the Fab–X31 BHA complex was solved
by molecular replacement using the AMoRe package
(Navaza, 1994). The structure was refined by simulated
annealing of torsion angle parameters as implemented
in CNS (Brunger et al., 1998; Rice and Brunger, 1994)
followed by grouped B-factor refinement. During refine-
ment noncrystallographic symmetry constraints were ap-
plied to the three subunits of the HA trimer and sepa-
rately to the two constant-domain dimers and the two
variable-domain dimers of the Fabs (the resulting rmsd of
noncrystallographic symmetry-related groups was 0.2 Å).
After a few cycles of refinement, the complementarity
determining regions were built into the electron density.
All maps were computed with the CNS package (Brunger
et al., 1998) and visualized in Turbo Frodo (Roussel and
Cambillau, 1991). Refinement statistics are displayed in
Table 1. The stereochemistry of the final model is that
expected at 3.5 Å resolution.
Hemagglutinin low pH conformational changes
The pH of the HA–Fab complex solution in 0.015 M
NaCl was adjusted, at room temperature, by adding 0.1
M citric acid; after 10 min, the pH was adjusted back to
7.3 with 1.0 M Tris–HCl; samples were processed in two
different ways (Skehel et al., 1982). (a) Trypsin digestion.
Trypsin was added to HA or to the HA:Fab complex at a
20:1 HA:trypsin ratio (w/w) for 10 min at 20°C. Tryptic
products were analyzed by polyacrylamide gel electro-
phoresis using 16% acrylamide gels under reducing con-
ditions. (b) Sucrose density-gradient centrifugation. The
free and Fab-complexed X31 HA solutions were layered
onto 5–25% sucrose density gradients and centrifuged at
30,000 rpm and 20°C for 16 h in an SW41 Beckman rotor.
Measurements of the affinities of the Fab for viral HA
X31 virus and mutant virus at concentrations ranging
from 6 ng/ml to 200 g/ml were incubated overnight at
20°C with 20 pM Fab in PBS, pH 7.0, containing 0.02%
(w/v) BSA. We evaluated HA concentration by comparing
the intensity of the HA band of whole virus on a Coo-
massie-stained SDS–PAGE gel to those of known
amounts of HA. The mixture was then briefly centrifuged
through a Centricon 500 (Amicon), until 10% of the total
volume had filtered through. In this way the equilibrium
of the virus with the binding species is minimally per-
turbed and the filtrate contains Fab at a concentration
equal to its free concentration in the mixture with the
virus. The Fab concentration in the filtrate was evaluated
using a standard ELISA procedure, coating X31 virus on
microplates (Friguet et al., 1989). The measured affinities
were 1.7 1010 M (X31 HA), 7.8 107 M ( 224–230 X31
HA), and 1.1 107 M (S193N, L226P X31 HA).
FIG. 2. The Fab’s interference with HA low pH structural transition. (a)
Susceptibility of HA and HA:Fab complexes to tryptic digestion after
incubation at low pH; an SDS gel of the digestion products is pre-
sented. From left to right: uncomplexed HA, a complex of HA with a
control Fab whose epitope is comprised in an HA monomer (Fleury et
al., 1999), and a complex of HA with the Fab we studied. (b) Sucrose
density fractionation of HA and of the complex of HA with the studied
Fab after incubation at pH 7 (E), pH 5 (ƒ), and pH 4.2 (‚). Filled
symbols indicate complexed HA (studied only at pH 7 and 4.2); empty
symbols represent uncomplexed HA; 0.8-ml fractions were collected
from the bottom of the gradient (fraction 1) while optical density was
continuously recorded.
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Coordinates
Coordinates have been deposited in the Protein Data
Bank (code: 1KEN).
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